Deal Library / Pharma BD Deal Intelligence

Swedish Orphan Biovitrum AB — Pharma Deals

The Pharma Closeout tracks 6 deals, $7.6B in disclosed deal value, 4 with a post-close Outcome Score for Swedish Orphan Biovitrum AB.

Median Critic Score: 71  ·  Median Outcome Score: 74

Best outcome: Swedish Orphan Biovitrum AB / Biovitrum (84)  ·  Weakest outcome: Swedish Orphan Biovitrum AB / CTI BioPharma Corp. (60)

All 6 deals

• Swedish Orphan Biovitrum AB / Biovitrum — 2001 · $493M · Worked — the deal delivered on its rationale.
• Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) — 2018 · $2.3B · Worked — the deal delivered on its rationale.
• Swedish Orphan Biovitrum AB / Innate Pharma SA — 2026 · $580M · Largely worked — most objectives met.
• Swedish Orphan Biovitrum AB / CTI BioPharma Corp. — 2023 · $1.7B · Largely worked — most objectives met.
• Swedish Orphan Biovitrum AB / Arthrosi Therapeutics, Inc. — 2025 · $1.5B
• Swedish Orphan Biovitrum AB / Apellis Pharmaceuticals, Inc. — 2020 · $1.0B

← Deal Library  ·  Interactive search  ·  How we score deals